Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Evolving Treatment Patterns in Breast Cancer

EP. 1: A Background on Early HER2+ Breast Cancer

January 14th 2019

EP. 2: HER2+ Breast Cancer: The KATHERINE Trial

January 14th 2019

EP. 3: HER2+ Breast Cancer: Use of Weekly Paclitaxel-Trastuzumab

January 14th 2019

EP. 4: Pathologic Complete Response in HER2+ Breast Cancer

January 14th 2019

EP. 5: Current State of CDK4/6 Inhibition in HR+ mBC

January 14th 2019

EP. 6: HR+ Metastatic Breast Cancer: Upfront CDK4/6 Inhibition

January 14th 2019

EP. 7: Making Sense of Adjuvant Therapy in HER2+ Breast Cancer

January 14th 2019

EP. 8: HER2+ Breast Cancer: Neratinibs Role as Adjuvant Therapy

January 14th 2019

EP. 9: Moving CDK4/6 Inhibition to HER2+ Breast Cancer

January 14th 2019

EP. 10: Chemoimmunotherapy in TNBC: The IMpassion130 Trial

January 14th 2019

EP. 11: Combining PARP and Checkpoint Inhibitors in TNBC

January 14th 2019

EP. 12: Antibody-Drug Conjugates in TNBC: Sacituzumab Govitecan

January 14th 2019

EP. 13: Questioning CDK4/6 Inhibitor Cross-Resistance in HR+ mBC

January 14th 2019

EP. 14: Chemoimmunotherapy in TNBC: The KEYNOTE-355 Trial

January 14th 2019
Advertisement
Advertisement

Trending on OncLive

1

Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026

2

International Intel: A Glance at the Top Global Breast Cancer News From April-June 2026

3

MYTHOS Misses Prespecified ORR End Point With T-DXd in HER2-Low Salivary Gland Carcinoma

4

Orelabrutinib Generates Significant Survival Benefits in Treatment-Naive CLL

5

Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us